RZB Overview

Expansion in New York City: Reinsurance Group of America (RGA) has opened its first office in New York City at Park Avenue Tower, emphasizing its focus on high-quality assets in prime locations while continuing to grow its international premium volumes, particularly in Asia.

Impact of GLP-1 Medications: A study by RGA suggests that widespread use of GLP-1 medications could lead to a 3.5% reduction in US mortality by 2045, highlighting the company's engagement with emerging healthcare trends that may influence risk assessment in the insurance sector.

Financial Projections and Capital Strength: RGA projects $29.2 billion in revenue and $1.9 billion in earnings by 2028, requiring significant annual growth, while its strong balance sheet and deployable capital position it well for future growth opportunities despite exposure to US health claim volatility.

Diverse Fair Value Estimates: Community fair value estimates for RGA range from $195 to $613, reflecting differing opinions on the company's worth, with recent volatility in US claims patterns adding complexity to investment considerations.

Management Insights: RGA reported Q2 2025 operating EPS of $4.72, below expectations due to claims volatility in U.S. individual life and healthcare excess business; however, they closed the Equitable transaction, increasing capital flexibility for growth and shareholder returns.

Outlook and Concerns: Management remains confident in long-term prospects despite short-term challenges, expecting improved operating income from the Equitable transaction while addressing analysts' concerns about claims volatility and the timing of share repurchases.

Stock Downgrade: Raymond James Financial downgraded Reinsurance Group of America (NYSE:RGA) from "Strong Buy" to "Market Perform," citing increased competition and market challenges affecting the company's outlook, despite strong Q1 2025 results.

Market Concerns: The firm highlighted concerns over a temporary pause in the US jumbo pension risk transfer market and diminishing returns on UK buy-in PRTs, leading to a less optimistic view on RGA's future earnings potential.

Management Insights: RGA reported strong Q1 2025 earnings with adjusted operating earnings of $5.66 per share and a 15% return on equity, driven by favorable claims experience and strategic capital deployment, including significant transactions in Asia.

Outlook and Growth: Management expressed optimism for future growth, particularly from the Equitable transaction expected to enhance earnings, while maintaining confidence in their disciplined risk management and the Creation Re strategy to drive profitability across regions.

Earnings Performance: RGA reported strong fourth-quarter results for 2024, achieving adjusted operating earnings of $4.99 per share and a record $1.7 billion in capital deployment, leading to an increased intermediate-term ROE target of 13%-15% and reaffirmed growth targets of 8%-10%.

Strategic Growth Initiatives: The company is focusing on expanding its business in Asia and the US, with notable growth in traditional and financial solutions sectors, while optimizing its balance sheet through strategic transactions and enhancing risk management practices.